JNJ

238.71

-0.54%↓

UNH

277.86

+0.52%↑

TMO

542.43

+0.07%↑

ABT

110.77

-0.05%↓

ISRG

493.16

+1.21%↑

JNJ

238.71

-0.54%↓

UNH

277.86

+0.52%↑

TMO

542.43

+0.07%↑

ABT

110.77

-0.05%↓

ISRG

493.16

+1.21%↑

JNJ

238.71

-0.54%↓

UNH

277.86

+0.52%↑

TMO

542.43

+0.07%↑

ABT

110.77

-0.05%↓

ISRG

493.16

+1.21%↑

JNJ

238.71

-0.54%↓

UNH

277.86

+0.52%↑

TMO

542.43

+0.07%↑

ABT

110.77

-0.05%↓

ISRG

493.16

+1.21%↑

JNJ

238.71

-0.54%↓

UNH

277.86

+0.52%↑

TMO

542.43

+0.07%↑

ABT

110.77

-0.05%↓

ISRG

493.16

+1.21%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

139 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. veebr 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. veebr 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. veebr 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. veebr 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. veebr 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. veebr 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. veebr 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. veebr 2026, 02:46 UTC

Omandamised, ülevõtmised, äriostud

Big Money, High Anxiety -- Barrons.com

6. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. veebr 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. veebr 2026, 21:17 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. veebr 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. veebr 2026, 21:13 UTC

Tulu

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. veebr 2026, 21:13 UTC

Tulu

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. veebr 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. veebr 2026, 20:34 UTC

Tulu

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

139 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.